Brief: Krystal Biotech reports Q4 net loss per share of USD 1.25
27/02/2023 12:02
Feb 27 (Reuters) - Krystal Biotech Q4 operating expenses USD 34.771 million. * Q4 net income USD -32.052 million * Q4 EPS USD -1.25
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion